Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237939
Status:
COMPLETED
Last Update Posted:
2013-11-08
First Post:
2005-10-11
Brief Title:
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Study Overview
Official Title:
A Prospective Multicenter Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices Broad Effectiveness Trial With Aripiprazole- BETA
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None